COMPASS Pathways Inc.
NASDAQ: CMPS
Company Overview
The company's focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The team is pioneering the development of a new model of psilocybin therapy, in which their proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support.
COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and the company is currently conducting a phase IIb clinical trial of psilocybin therapy for TRD, in 20 sites across Europe and North America.
The company is headquartered in London, UK, with offices in New York, USA.
Financial Highlights
$0
Revenue (ttm)
$0
Gross Profit (ttm)
-$1.94
Diluted EPS (ttm)
Management Team
Mr. George Jay Goldsmith
Co-Founder, Chairman & CEO
Dr. Ekaterina Malievskaia M.D.
Co-Founder, Chief Innovation Officer & Exec. Director
Dr. Guy Goodwin
Chief Medical Officer
Mr. Michael F. Falvey
Chief Financial Officer
Dr. Greg Ryslik Ph.D.
Exec. VP of AI, Engineering, Digital Health Research & Technology
Mr. Stephen D. Schultz
Sr. VP of Investor Relations
Mr. Matthew Owens
Gen. Counsel & Chief Legal Officer
Ms. Anne Benedict
Chief People Officer
Mr. Lars Christian Wilde
Sr. Advisor
Mr. Marco Mohwinckel
Chief Commercial Officer
Key Highlights
Market Capitalization
$375,897,574
Shares Outstanding
34,805,331
Shares Short (% of Float)
()
Insider Ownership
49%